// App-Quantinova.ai

291 : ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL

Researchers

Presenter

  • Huimin Geng

Principal Investigators

  • Maike Buchner

  • Lars Klemm

  • Kaveh Hemati

  • Seyedmehdi Shojaee

  • Mak W Tak

  • John E Coligan

  • William L. Carroll

  • Cheryl L Willman

  • Markus Muschen

Medical Centers

  • The Campbell Family Institute for Cancer Research and Ontario Cancer Institute, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Philadelphia chromosome–positive (Ph+) ALL

Biomarkers

  • Breakpoint Cluster Region

  • p53

  • Cluster of Differentiation 31

  • Proto-oncogene tyrosine-protein kinase ROS

  • Src homology region 2 domain-containing phosphatase-1

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved